Much of the $26 billion opioid settlement agreement announced in early 2022 will be used to fund state and subdivision initiatives for abatement of the opioid epidemic. However, not all lawsuits are settled. In this session, topics of discussion include:

• Lessons learned from the settled lawsuits and mitigation strategies for every link in the supply chain
• Evaluating the arguments concerning unlawful advertising and promotion of the consequences for manufacturers
• Identifying the arguments surrounding diversion and the consequences for distributors and pharmacies
• Update on the $26 billion settlement agreement
• What are the abatement initiatives and how will they be implemented
• Reviewing the lawsuits that have not settled and comparing the different legal arguments
• Analyzing the findings of the Johnson & Johnson Oklahoma trial and the implications for multidistrict litigation
• Making the strategic decision between judge-alone or jury trials